KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to $71.8 million.

  • Acadia Pharmaceuticals' Income from Continuing Operations rose 11913.63% to $71.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $261.2 million, marking a year-over-year increase of 10333.39%. This contributed to the annual value of $226.5 million for FY2024, which is 46919.75% up from last year.
  • Acadia Pharmaceuticals' Income from Continuing Operations amounted to $71.8 million in Q3 2025, which was up 11913.63% from $26.7 million recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Income from Continuing Operations ranged from a high of $143.8 million in Q4 2024 and a low of -$113.1 million during Q1 2022
  • Its 5-year average for Income from Continuing Operations is -$5.3 million, with a median of -$14.5 million in 2021.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first crashed by 13948.56% in 2023, then skyrocketed by 289820.47% in 2024.
  • Acadia Pharmaceuticals' Income from Continuing Operations (Quarter) stood at -$43.1 million in 2021, then rose by 3.29% to -$41.7 million in 2022, then soared by 209.77% to $45.7 million in 2023, then soared by 214.23% to $143.8 million in 2024, then plummeted by 50.05% to $71.8 million in 2025.
  • Its last three reported values are $71.8 million in Q3 2025, $26.7 million for Q2 2025, and $19.0 million during Q1 2025.